Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study

Diabetes Care. 2022 May 1;45(5):e93-e96. doi: 10.2337/dc21-1917.

Peter Ueda¹, Henrik Svanström^{1

2}, Anders Hviid^{2

3}, Björn Eliasson^{2

4}, Ann-Marie Svensson^{4

5}, Stefan Franzén^{5

6}, Soffia Gudbjörnsdottir^{4

5}, Kristian Hveem^{7

8}, Christian Jonasson^{7

8

9}, Viktor Wintzell¹, Mads Melbye^{10

11}, Björn Pasternak^{1

2}

¹ Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
² Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
³ Pharmacovigilance Research Center, Department of Drug Development and Clinical Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁴ Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
⁵ Swedish National Diabetes Register, Västra Götalandsregionen, Gothenburg, Sweden.
⁶ Health Metrics, Department of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁷ K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology, Trondheim, Norway.
⁸ HUNT Research Centre, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Levanger, Norway.
⁹ Division of Health Data and Digitalization, Norwegian Institute of Public Health, Oslo, Norway.
¹⁰ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
¹¹ Department of Medicine, Stanford University School of Medicine, Stanford, CA.

No abstract available

Publication types